Denali Therapeutics Inc.
DNLI
$19.00
$1.166.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -0.73% | -11.64% | |||
| Gross Profit | 0.73% | 11.64% | |||
| SG&A Expenses | 9.97% | 9.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.83% | -7.29% | |||
| Operating Income | -1.83% | 7.29% | |||
| Income Before Tax | -2.24% | 6.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.24% | 6.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.24% | 6.66% | |||
| EBIT | -1.83% | 7.29% | |||
| EBITDA | -1.96% | 7.98% | |||
| EPS Basic | -1.67% | 6.79% | |||
| Normalized Basic EPS | -1.66% | 9.43% | |||
| EPS Diluted | -1.67% | 6.79% | |||
| Normalized Diluted EPS | -1.66% | 9.43% | |||
| Average Basic Shares Outstanding | 0.57% | 0.13% | |||
| Average Diluted Shares Outstanding | 0.57% | 0.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||